Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New paper published in Nature Communications from researchers in Respiratory Medicine Unit, NDM Experimental Medicine'

Mucosal-associated invariant T (MAIT) cells are a recently-discovered type of white blood cell which are believed to play an important role in protecting humans, and many other mammals, from infections. They are able to detect minute quantities of vitamin metabolites produced in cells infected with bacteria and yeasts, but so far they have not been shown to protect against a major human disease. In work undertaken at the University of Melbourne, and published in the journal Nature Communications, the team and I have shown that in humans and animals MAIT cells can respond to two strains of Legionella: the bacterium which causes the very serious lung infection, Legionnaire’s disease. Importantly we showed in mice that having MAIT cells improves the chances of survival. For the first time we also showed that this protection against disease could be improved by activating these cells with vitamin metabolites. This could be an exciting new approach to protecting people against serious lung infections.

Find out more (Nature Communications)

Similar stories

Outbreak: fighting coronavirus

In a new Oxford Science Blog, Charvy Narain (Communications & Public Engagement Manager, Radcliffe Department of Medicine) talks to some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak.

Researchers find new cells that repair tissue

Researchers from Nuffield Department of Medicine have discovered that a newly discovered group of cells can help repair tissues in the body.

Rapidly spreading multidrug-resistant parasites render frontline malaria drug ineffective in southeast Asia

A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.

New study shows faster way to cure vivax malaria

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

Award-winning citizen science project tackling TB gets millionth classification

An award-winning Oxford-based international project to tackle antibiotic resistance has achieved its one millionth classification.

UK-led study marks shift towards genetic era in tackling TB

In a landmark study that may herald a quicker, more tailored treatment for the millions of people around the world living with tuberculosis (TB), UK researchers have shown how our understanding of TB’s genetic code is now so detailed that we can now predict which commonly used anti-TB drugs are best for treating a patient’s infection and which are not.